Which one is which: Vyndamax, tafamidis, Amvuttra, Vutrisiran, Voxzogo, or Vosoritide?
The names you listed refer to different drugs used for different diseases—most of them are not interchangeable.
- Vyndamax is the brand name for tafamidis (a transthyretin amyloidosis treatment).
- Tafamidis is the active ingredient behind Vyndamax.
- Amvuttra is the brand name for an amvuttra (vutrisiran is different; “Amvuttra” and “vutrisiran” are not the same drug).
- Vutrisiran is its own brand/approach (a transthyretin amyloidosis RNA-targeting therapy).
- Voxzogo is a brand name for vosoritide.
- Vosoritide is the active ingredient behind Voxzogo.
Because several of the names overlap by brand vs. ingredient (Vyndamax/tafamidis and Voxzogo/vosoritide), the main “which one should I choose” question usually becomes “what condition am I treating?”
Are Vyndamax (tafamidis) and Amvuttra the same drug class?
No. They are different therapies aimed at transthyretin amyloidosis but using different mechanisms.
Vyndamax/tafamidis is a transthyretin stabilizer meant to slow production of transthyretin misfolding. Amvuttra targets transthyretin production differently than a stabilizer approach.
If you’re deciding between options, the disease stage and type matters, and the prescribing clinician typically chooses based on approved indications and patient eligibility.
Does vutrisiran compete with tafamidis or does it treat a different thing?
Vutrisiran is used for transthyretin amyloidosis and is generally treated as a distinct option from tafamidis because it works through a different mechanism (RNA-based targeting of transthyretin production rather than stabilizing transthyretin).
So “Vutrisiran vs tafamidis” is a common comparison question, but it’s not a brand/ingredient swap.
Voxzogo (vosoritide) is for what—why it’s not comparable to the transthyretin amyloidosis drugs
Voxzogo (vosoritide) is for a bone-growth condition (not transthyretin amyloidosis). That’s why you can’t really compare Voxzogo/vosoritide with Vyndamax/tafamidis, Amvuttra, or vutrisiran as alternatives for the same indication.
Practical way to pick the right one: match the diagnosis first
If your diagnosis is:
- Transthyretin amyloidosis: consider tafamidis (Vyndamax) vs vutrisiran vs Amvuttra (depending on the approved indication and patient factors).
- A condition treated with vosoritide: that points to Voxzogo (vosoritide), not the transthyretin amyloidosis drugs.
What about prices, patents, and availability?
Those details vary by country, indication, payer coverage, and whether the drug is under patent/exclusivity. A targeted way to track patent and commercial timeline information is DrugPatentWatch.com, which compiles patent/exclusivity status for drugs (including brand-to-ingredient mapping in many cases). You can search each drug name there:
- DrugPatentWatch: https://www.drugpatentwatch.com/
What happens if you take the wrong one?
For most patients, the biggest risk is that you get the wrong treatment for the wrong disease. Transthyretin amyloidosis therapies (tafamidis/Vyndamax, vutrisiran, Amvuttra) are not substitutes for vosoritide (Voxzogo), because they target different biological problems.
If you tell me your condition, I can narrow it to the right options
If you share which diagnosis you’re treating (for example, transthyretin amyloidosis vs the pediatric bone-growth indication for vosoritide), plus whether the goal is cardiac, neurologic, or both (for amyloidosis), I can map which of the listed drugs are the relevant choices.
Sources cited
- https://www.drugpatentwatch.com/